METHOD FOR PREDICTING CLINICAL BENEFIT IN THE TREATMENT OF NEURODEVELOPMENTAL, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 6, 2014
app pub date -
Aug 21, 2012
filing date -
Aug 26, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully